company background image
LNTH

Lantheus HoldingsNasdaqGM:LNTH Stock Report

Market Cap

US$1.9b

7D

-2.8%

1Y

111.8%

Updated

26 Nov, 2021

Data

Company Financials +
LNTH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

LNTH Stock Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Rewards

Earnings are forecast to grow 77.83% per year

Risk Analysis

No risks detected for LNTH from our risk checks.

Lantheus Holdings Competitors

Cardinal Health

NYSE:CAH

US$13.4b

Jubilant Pharmova

BSE:530019

₹94.9b

Price History & Performance

Summary of all time highs, changes and price drops for Lantheus Holdings
Historical stock prices
Current Share PriceUS$27.89
52 Week HighUS$31.60
52 Week LowUS$12.97
Beta1.33
1 Month Change23.74%
3 Month Change8.56%
1 Year Change111.77%
3 Year Change48.75%
5 Year Change204.81%
Change since IPO333.75%

Recent News & Updates

Nov 13
Would Lantheus Holdings (NASDAQ:LNTH) Be Better Off With Less Debt?

Would Lantheus Holdings (NASDAQ:LNTH) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

LNTHUS Medical EquipmentUS Market
7D-2.8%-4.5%-2.7%
1Y111.8%13.4%21.3%

Return vs Industry: LNTH exceeded the US Medical Equipment industry which returned 13.4% over the past year.

Return vs Market: LNTH exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is LNTH's price volatile compared to industry and market?
LNTH volatility
LNTH Average Weekly Movement5.4%
Medical Equipment Industry Average Movement7.2%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: LNTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: LNTH's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1956595Mary Heinohttps://www.lantheus.com

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical.

Lantheus Holdings Fundamentals Summary

How do Lantheus Holdings's earnings and revenue compare to its market cap?
LNTH fundamental statistics
Market CapUS$1.89b
Earnings (TTM)-US$34.48m
Revenue (TTM)US$389.80m

4.8x

P/S Ratio

-54.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LNTH income statement (TTM)
RevenueUS$389.80m
Cost of RevenueUS$221.34m
Gross ProfitUS$168.46m
ExpensesUS$202.94m
Earnings-US$34.48m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin43.22%
Net Profit Margin-8.84%
Debt/Equity Ratio35.5%

How did LNTH perform over the long term?

See historical performance and comparison

Valuation

Is Lantheus Holdings undervalued compared to its fair value and its price relative to the market?

3.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: LNTH ($27.89) is trading above our estimate of fair value ($8.03)

Significantly Below Fair Value: LNTH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LNTH is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: LNTH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LNTH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LNTH's PB Ratio (3.8x) is in line with the US Medical Equipment industry average.


Future Growth

How is Lantheus Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

77.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LNTH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: LNTH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LNTH's is expected to become profitable in the next 3 years.

Revenue vs Market: LNTH's revenue (15.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: LNTH's revenue (15.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LNTH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Lantheus Holdings performed over the past 5 years?

-37.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LNTH is currently unprofitable.

Growing Profit Margin: LNTH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LNTH is unprofitable, and losses have increased over the past 5 years at a rate of 37.3% per year.

Accelerating Growth: Unable to compare LNTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LNTH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: LNTH has a negative Return on Equity (-6.9%), as it is currently unprofitable.


Financial Health

How is Lantheus Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: LNTH's short term assets ($201.5M) exceed its short term liabilities ($76.9M).

Long Term Liabilities: LNTH's short term assets ($201.5M) do not cover its long term liabilities ($271.6M).


Debt to Equity History and Analysis

Debt Level: LNTH's net debt to equity ratio (17.2%) is considered satisfactory.

Reducing Debt: LNTH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: LNTH's debt is well covered by operating cash flow (22.9%).

Interest Coverage: Insufficient data to determine if LNTH's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Lantheus Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LNTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LNTH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LNTH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LNTH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LNTH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Mary Heino (61 yo)

6.25yrs

Tenure

US$4,326,357

Compensation

Ms. Mary Anne Heino has been the Chief Executive Officer and President of Lantheus Holdings, Inc. since August 2015. Ms. Heino served as Chief Operating Officer at Lantheus Medical Imaging, Inc. since Marc...


CEO Compensation Analysis

Compensation vs Market: Mary's total compensation ($USD4.33M) is about average for companies of similar size in the US market ($USD3.64M).

Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LNTH's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: LNTH's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lantheus Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lantheus Holdings, Inc.
  • Ticker: LNTH
  • Exchange: NasdaqGM
  • Founded: 1956
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.888b
  • Shares outstanding: 67.69m
  • Website: https://www.lantheus.com

Number of Employees


Location

  • Lantheus Holdings, Inc.
  • 331 Treble Cove Road
  • North Billerica
  • Massachusetts
  • 1862
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:14
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.